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Summary The effects of steroid hormones are pleiotropic. Similarly, non-steroidal oestrogen receptor
antagonists such as tamoxifen exert partial agonistic effects with a species- and tissue-specific pattern.
Conversely, little is known of the biological effects of non-steroidal anti-androgens, whose role has been
investigated in the palliative treatment of prostate cancer. We studied the effects of the non-steroidal
anti-androgen nilutamide on parameters of red blood cells, an androgen-dependent cell compartment, in 24
men with prostate cancer and compared the results with those obtained in 38 historical control patients treated
with D-tryptophan-6-LHRH. Administration of the anti-androgen induced a limited rise in testosterone
concentrations (from 14.1 ± 1.8 up to a maximum of 19.6 ± 2.3 nmol l-l) and a significant increase with time
in haemoglobin and haematocrit (y = 12.6 g dl-I + 0.15 months and y = 37.3% + 0.46 months respectively,
P = 0.008 for both), while no change occurred in red blood cell count (y = 4.19 x 106 mm-3 + 0.02 months,
P = 0.2). Conversely, no variation in erythroid parameters was observed in the patients treated with the
LHRH analogue (haemoglobin = 12.7 + 0.02 months, P = 0.59; haematocrit = 38.1 + 0.02 months, P = 0.9;
red blood cells = 4.34 x 106 mm-3 + 0.15 months, P = 0.4). The difference between the linear regression slopes
of haemoglobin in the two treatment groups was significant (F-ratio = 3.39, P = 0.03). While the stimulation
of erythropoiesis induced by the anti-androgen might be due to incomplete neutralisation of endogenous
androgens at the bone marrow level, a cell-specific agonistic effect of the drug cannot be excluded, thus calling
into question the designation of pure antagonists which has been attributed to this class of compounds.
Ongoing randomised trials should address this issue.
Orchiectomy or LHRH agonists represent the standard
endocrine treatment of advanced prostatic cancer. An impor-
tant drawback in palliative management of sexually active
patients, however, is the loss of libido and sexual potency
which accompanies testosterone (T) suppression. In recent
studies, it has been shown that the administration of pure
non-steroidal androgen receptor (AR) antagonists is able to
interfere with the androgen negative feedback, resulting in a
paradoxical state of hypergonadotropic hypergonadism
(Gooren et al., 1987), which allowed the preservation of
libido and sexual potency in some patients (Sogani et al.,
1984; Decensi et al., 1991; Tyrrel, 1992). For this reason, the
use of non-steroidal anti-androgens as single agents has been
sought as a potential improvement in the palliative manage-
ment of prostate cancer. Moreover, their broader use has
been proposed in the management of androgen-related non-
oncological conditions (Marcondes et al., 1992) and even in
the chemoprevention of prostate cancer (Crawford et al.,
1992).
At present, however, little is known not only of the clinical
anti-tumour activity but also of the spectrum of biological
effects resulting from administration of this class of com-
pounds as single agents. A better understanding of this issue
may be important, particularly when taking into account the
heterogeneity that characterises the effects both of steroids
and steroid antagonists at target level (Green, 1990;
Gronemeyer, 1992; Landers & Spelsberg, 1992). The non-
steroidal anti-oestrogen tamoxifen is the prototype of this
pleiotropism, also having significant agonistic properties
which are species, tissue, cell and response specific (Nayfield
et al., 1991).
The role of androgens in the physiological regulation of
erythropoiesis is well established (Fried & Morley, 1985).
Within the normal range of haemoglobin (Hb), stimulation
of erythropoiesis by androgens is not mediated by significant
changes in erythropoietin levels (Weber et al., 1991) but is
directly exerted by a nuclear AR (Claustres & Sultan, 1988).
Thus, the red blood cell compartment may represent a target
of biological activity of AR antagonists.
In the present work, the effect of administration of the
non-steroidal anti-androgen nilutamide on erythroid
parameters was studied in untreated patients with prostate
cancer and the results were compared with those induced in a
historical control group by administration of the analogue
D-tryptophan (Trp)-6-LHRH. Treatment with the anti-
androgen induced a significant increase in red blood series
parameters both with time and in comparison with LHRH
agonist treatment. The potential mechanisms subserving this
phenomenon are discussed.
Materials and methods
The study population consisted of a series of 24 men in the
anti-androgen group (median age, 71, range 57-78) and of 38
men in the GnRH agonist group (median age 72.5 years,
range 60-78) seen at the authors' institution as part of two
consecutive phase II clinical trials performed by the Italian
Prostatic Cancer Project (Boccardo et al., 1987; Decensi et
al., 1991). Patients were affected with metastatic (stage D2)
prostate cancer and had received no prior treatment. In-
clusion criteria for the study were good performance status
and life expectancy greater than 6 months. Informed consent
was obtained from each patient after the trials had been
approved by the Institutional Review Board of the National
Cancer Research Institute of Genoa.
Treatment consisted of either sustained-release (depot)
D-Trp-6-LHRH (Decapeptyl, Ipsen Biotech, Milan, Italy),
administered as a 3.75 mg 4 weekly intramuscular dose or the
anti-androgen nilutamide (Anandron, Roussel Pharma,
Milan, Italy), taken at the daily oral dose of 300 mg (two
50 mg tablets every 8 h). Treatments continued until disease
progression.
Blood samples for measurement of Hb (gdl1), haemato-
crit (Hct)(%), red blood cells (RBC)(n x 106mm-3), platelets
(Plt)(n x I03mm-3) and testosterone (T) (nmolI1) levels
were taken between 08.00 and 09.00 h before treatments and
subsequently at 3 month intervals. Blood parameters were
measured on a Coulter Counter JT3. Testosterone concentra-
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Figure 1 Effect of administration of the anti-androgen nilutamide (top row) or D-tryptophan-6-LHRH (bottom row) on
haemoglobin (Hb), haematocrit (Hct) and red blood cells (RBC). The difference between the regression slopes of Hb is significant
(F-ratio = 3.39, P = 0.03).
tions were determined in a subset of 14 and 22 patients in the
anti-androgen and LHRH agonist group, respectively, by
liquid-phase radioimmunoassay (RIA) using a commercially
available kit purchased from Diagnostic Products (Los
Angeles, CA, USA). The intra- and interassay coefficients of
variation were 7% and 10% respectively. The reference range
in normal men (age 17-75) was 9.4-37rnmol -'.
All results are given as the mean ± s.e. The t-test was
applied to test differences in Hb between two independent or
dependent samples. Within each group, the effect of treat-
ment time on blood parameters and hormone levels was
analysed by linear regression and by non-parametric two-way
analysis of variance (Friedman ANOVA) respectively. The
differences between the slopes of the regression lines
generated by haematological data of the two treatment
groups were analysed using ANOVA of regression
coefficients.
Results
Before treatment there were no differences in red blood cell
parameters and platelet levels between the two treatment
groups (Hb, 12.6 ± 0.3 vs 12.7 ±0.3 g dl-', P = 0.8; Hct,
37.3 1.1 vs 38.1 ± 0.9%, P = 0.5; RBC, 4.19 ± 0.1 vs
4.34±0.1 x 106mm-3, P=0.2; Plt, 236± 16.2 vs 262±
14.3 x 103 mm-3, P = 0.1; anti-androgen and LHRH agonist
group respectively).
The effects of the treatments on the values of Hb, Hct and
RBC are shown in Figure 1. There was a significant increase
with time in both Hb (y = 12.6 + 0.15 months, P = 0.008)
and Hct (y = 37.3 + 0.46 months, P =0.008) during anti-
androgen administration, while RBC remained unchanged
(y = 4.19 x 106 + 0.02 months, P = 0.2). No significant varia-
tion in Plt occurred (y = 236 x 103 + 3.94 months, P = 0.3).
A plot of the change in Hb for individual patients after 3
months of anti-androgen is shown in Figure 2. The data
indicate a general increase in Hb values affecting the patient
population as a whole, with a mean Hb of 0.8 ± 0.2 g dl-'
(P = 0.004). In the LHRH agonist group, no variation in red
blood cell parameters was noted (Figure 1): Hb
(y = 12.7 + 0.02 months, P = 0.59), Hct (y = 38.1 + 0.02
months, P = 0.9), RBC (y = 4.34 x 106 + 0.15 months,
P= 0.4). Nor was there any significant variation in Plt values
(y= 262 x I03 - 1.2 months, P = 0.58).
The difference in regression coefficients between the two
treatment groups (indicating a different slope of the lines)
was statistically significant for Hb (F-ratio = 3.39, P = 0.03),
while no such difference was evident for Hct (F-ratio = 2.32,
P = 0.1), RBC (F-ratio = 0.7, P = 0.47) and Plt (F-
ratio = 0.8, P = 0.45).
Testosterone concentrations initially and after 3, 6 and 9
months were 14.1 ± 1.8, 19.6 + 2.3, 18 ± 2.2 and 18.9 +
2.2 nmol 1- respectively in the anti-androgen group (P<
0.05) and 17.3 ± 1.3, 0.6 ± 0.2, 0.5 ± 0.2 and 0.3 ± 0.1 nmol
1- respectively in the LHRH agonist group (P<0.001).
Discussion
Our data show that administration of the non-steroidal anti-
androgen nilutamide in men with prostate cancer induces a
significant increase in erythroid parameters. On theoretical
grounds, several explanations may be advocated: (1) recovery
of bone marrow reserve after tumour growth inhibition; (2)
inadequate neutralisation of increased circulating androgens
by the anti-androgen; (3) an agonistic effect elicited by the
anti-androgen on the AR at the erythroid precursor level;
and (4) increased activity of gonadal factors, such as activin,
known to exert a stimulatory effect on erythropoiesis in vivo
in rodents (Schwall et al., 1989).
Although the increase in red blood cell parameters
observed in the patients treated with the anti-androgen may
partly be the result of the anti-tumour effect on bone marrow
or of a non-specific improvement in general condition, the
lack of an increase in Plt levels and, more importantly, the
absence of any stimulatory effect in similar patients treated
with the LHRH agonist seem to argue against this as the
single mechanism.
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Figure 2 Plot of the change (A) in haemoglobin (Hb) for indi-
vidual subjects after 3 months of anti-androgen administration.
The mean (± s.e.) A Hb is also shown (dotted line).
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The occurrence of inadequate neutralisation of increased
androgens by the antagonist should also be considered, even
though' the increase in T concentrations was limited and the
results of pilot clinical trials seem to suggest a benefit in
terms of anti-tumour activity similar to conventional
androgen-suppressive manipulations (Decensi et al., 1991;
Benson, 1992; Tyrrel, 1992). This issue is currently the sub-
ject of randomised trials.
Although our observation could only be biased by the lack
of a randomised comparison, the concept of a potential
agonistic activity of nilutamide on erythroid parameters may
also be advanced. This would imply a differential control of
anti-androgen action in different target systems. Indeed, the
regulation of steroid hormone action is known to be complex
(Green, 1990; Gronemeyer, 1992; Landers & Spelsberg, 1992)
and steroid receptor antagonists exhibit biological effects that
are species, tissue, cell and response specific (Nayfield et al.,
1991). Recently, molecular biology studies have clearly
shown that the pleiotropic effect of the non-steroidal anti-
oestrogen tamoxifen is due to the selective activation of the
expression of target genes that depends on cell type and
promoter context, presumably through the interaction of the
ligand-receptor complex with different transcriptional fac-
tors (Berry et al., 1990; Green, 1990). Conversely, the
mechanisms of action and the pharmacology of non-steroidal
anti-androgens have been studied to a lesser extent. Indeed,
their characterisation as pure antagonists comes almost
exclusively from rodent studies using the ventral prostate as
target tissue (Poyet et al., 1985; Moguilewsky et al., 1986;
Furr et al., 1987). In keeping with the above, the definition of
pure antagonists is further challenged by the observation that
these compounds can induce de novo nuclear AR synthesis
(Steinsapir et al., 1991) and a sustained decline in prostate-
specific antigen levels after their discontinuation (Kelly &
Scher, 1993). The anti-tumour efficacy of nilutamide at a
lower dose (300mg daily for 1 month followed by 150mg
thereafter) was recently evaluated in combination with
orchiectomy in a randomised double-blind trial (Janknegt et
al., 1993). Among the reported adverse effects, anaemia was
observed in 4% of nilutamide-treated patients compared with
7% of placebo patients. Although this difference was not
statistically significant (X2 = 1.33, P = 0.24), a trend in favour
of a stimulatory effect on erythropoiesis cannot be excluded
if a continuous variable (i.e. the rise in Hb levels) were used
as an end point.
Whatever the mechanisms involved may be, randomised
trials currently in progress and mechanistic studies will fur-
ther elucidate our phenomenological observation and the
possible differences among various anti-androgens. The
potential role of growth factors such as activin also remains
to be established. In fact, in addition to the trophic effect on
erythropoiesis (Schwall et al., 1989), this member of the
transforming growth factor P family stimulates the secretion
of FSH (Schwall et al., 1989), another effect shared with
nilutamide administration (Decensi et dl., 1993).
In clinical terms, the trophic effect on erythropoiesis is
beneficial and does not necessarily raise questions on the
anti-tumour activity of this class of compounds in prostate
cancer, which still remains to be confirmed in comparative
controlled trials. They may well find a useful role in the
palliative management of selected patients in whom
maintenance of sexual activity is important.
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